share_log

福元医药(601089.SH):盐酸毛果芸香碱滴眼液获得药物临床试验批准通知书

Fuyuan Pharmaceutical (601089.SH): Maoguoyunxiang alkaloid hydrochloride eye drops obtained the Notice of Approval for Clinical Trials of Drugs.

Zhitong Finance ·  Nov 1, 2024 15:47

Fufeng Pharmaceutical (601089.SH) announced that recently, the company received the approval and issuance of the National Medical Products Administration...

According to the financial news app, Fufeng Pharmaceutical (601089.SH) issued an announcement recently, that the company has received the "Drug Clinical Trial Approval Notice" for the hydrochloride maobu yunxiang alkali eye drops approved and issued by the National Medical Products Administration. The company applied for the clinical trial of hydrochloride maobu yunxiang alkali eye drops, indicated for the treatment of presbyopia in adults, administered via ocular route, classified as a chemical drug Class 3. As of now, the company has invested approximately RMB 4.1066 million (unaudited) in the research and development of this product.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment